| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $713,346 | 3 | 12 |
Sells | $1,918,067 | 22 | 88 |
| WILSON TROY EDWARD | President and CEO | 3 | $713,346 | 1 | $327,419 | $385,928 |
| DOYLE THOMAS JAMES | SVP, Finance & Accounting | 0 | $0 | 3 | $130,297 | $-130,297 |
| FORD KATHLEEN | Chief Operating Officer | 0 | $0 | 4 | $162,853 | $-162,853 |
| Powl Brian T. | Chief Commercial Officer | 0 | $0 | 3 | $191,295 | $-191,295 |
| Bair Teresa Brophy | Chief Legal Officer | 0 | $0 | 4 | $243,744 | $-243,744 |
| Burrows Francis | Chief Scientific Officer | 0 | $0 | 2 | $248,982 | $-248,982 |
| Hasnain Faheem | director | 0 | $0 | 2 | $291,220 | $-291,220 |
| Leoni Mollie | Chief Medical Officer | 0 | $0 | 3 | $322,257 | $-322,257 |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Kura Oncology, Inc. have bought $713,346 and sold $1.92M worth of Kura Oncology, Inc. stock.
On average, over the past 5 years, insiders at Kura Oncology, Inc. have bought $644,173 and sold $1.1M worth of stock each year.
Highest buying activity among insiders over the last 12 months: WILSON TROY EDWARD (President and CEO) — $713,346.
The last purchase of 50,000 shares for transaction amount of $410,145 was made by WILSON TROY EDWARD (President & CEO) on 2025‑09‑08.
| 2025-12-18 | Sale | Burrows Francis | Chief Scientific Officer | 23,726 0.0271% | $9.78 | $231,931 | -3.15% | |
| 2025-12-09 | Sale | Hasnain Faheem | director | 10,000 0.0118% | $10.98 | $109,764 | -7.12% | |
| 2025-11-14 | Sale | Leoni Mollie | Chief Medical Officer | 15,485 0.0186% | $11.18 | $173,074 | -6.24% | |
| 2025-11-14 | Sale | Bair Teresa Brophy | Chief Legal Officer | 8,804 0.0106% | $11.18 | $98,401 | -6.24% | |
| 2025-11-14 | Sale | Powl Brian T. | Chief Commercial Officer | 8,887 0.0107% | $11.18 | $99,329 | -6.24% | |
| 2025-11-14 | Sale | DOYLE THOMAS JAMES | SVP, Finance & Accounting | 4,539 0.0055% | $11.18 | $50,732 | -6.24% | |
| 2025-11-14 | Sale | FORD KATHLEEN | Chief Operating Officer | 6,902 0.0083% | $11.18 | $77,143 | -6.24% | |
| 2025-09-29 | Sale | WILSON TROY EDWARD | President and CEO | 36,615 0.0421% | $8.94 | $327,419 | +13.94% | |
| 2025-09-29 | Sale | Leoni Mollie | Chief Medical Officer | 12,314 0.0141% | $8.94 | $110,114 | +13.94% | |
| 2025-09-29 | Sale | Bair Teresa Brophy | Chief Legal Officer | 8,805 0.0101% | $8.94 | $78,736 | +13.94% | |
| 2025-09-29 | Sale | DOYLE THOMAS JAMES | SVP, Finance & Accounting | 4,541 0.0052% | $8.94 | $40,607 | +13.94% | |
| 2025-09-29 | Sale | Powl Brian T. | Chief Commercial Officer | 8,891 0.0102% | $8.94 | $79,505 | +13.94% | |
| 2025-09-29 | Sale | FORD KATHLEEN | Chief Operating Officer | 6,892 0.0079% | $8.94 | $61,630 | +13.94% | |
| 2025-09-08 | WILSON TROY EDWARD | President & CEO | 50,000 0.0581% | $8.20 | $410,145 | +22.36% | ||
| 2025-08-13 | WILSON TROY EDWARD | President and CEO | 13,494 0.0159% | $6.64 | $89,623 | +50.77% | ||
| 2025-08-12 | WILSON TROY EDWARD | President and CEO | 36,506 0.0444% | $5.85 | $213,578 | +57.58% | ||
| 2025-05-19 | Sale | Bair Teresa Brophy | Chief Legal Officer | 1,559 0.0017% | $5.96 | $9,292 | +33.97% | |
| 2025-05-19 | Sale | FORD KATHLEEN | Chief Operating Officer | 1,558 0.0018% | $6.28 | $9,777 | +33.97% | |
| 2025-03-21 | Sale | Hasnain Faheem | director | 22,682 0.0287% | $8.00 | $181,456 | -2.42% | |
| 2025-01-28 | Sale | Bair Teresa Brophy | Chief Legal Officer | 7,281 0.0094% | $7.87 | $57,315 | -0.39% |
| WILSON TROY EDWARD | President and CEO | 246853 0.2837% | $2.13M | 3 | 14 | |
| Leoni Mollie | Chief Medical Officer | 225454 0.2591% | $1.95M | 0 | 3 | |
| Bair Teresa Brophy | Chief Legal Officer | 188139 0.2162% | $1.62M | 0 | 6 | |
| Powl Brian T. | Chief Commercial Officer | 139689 0.1605% | $1.21M | 0 | 3 | |
| DOYLE THOMAS JAMES | SVP, Finance & Accounting | 130257 0.1497% | $1.12M | 0 | 5 | |
| FORD KATHLEEN | Chief Operating Officer | 105373 0.1211% | $909,368.99 | 0 | 12 | |
| Burrows Francis | Chief Scientific Officer | 33735 0.0388% | $291,133.05 | 0 | 2 | |
| Hasnain Faheem | director | 23983 0.0276% | $206,973.29 | 0 | 2 | |
| EcoR1 Capital Fund Qualified, L.P. | 10 percent owner | 4408097 5.0658% | $38.04M | 8 | 1 | +14.44% |
| GUALBERTO ANTONIO | Head of Development & CMO | 339973 0.3907% | $2.93M | 0 | 1 | |
| Malley Thomas | director | 139557 0.1604% | $1.2M | 2 | 0 | <0.0001% |
| DALE STEPHEN | Chief Medical Officer | 38817 0.0446% | $334,990.71 | 0 | 3 | |
| FLOWERS KIRSTEN | CCO & Chief Strategy Officer | 20605 0.0237% | $177,821.15 | 0 | 1 | |
| GRASSO MARC | CFO, CBO | 0 0% | $0 | 0 | 4 |
$860,541,348 | 82 | -5.10% | $617.78M | |
$94,912,877 | 34 | -7.15% | $809.75M | |
$41,446,394 | 27 | 12.91% | $815.89M | |
$7,598,498 | 27 | 34.68% | $779.76M | |
$24,857,912 | 21 | -35.40% | $782.79M | |
$3,556,951 | 18 | 9.64% | $624.93M | |
$59,102,045 | 17 | 8.52% | $810.85M | |
$7,254,955 | 14 | 20.70% | $670.87M | |
$8,069,667 | 13 | -13.57% | $623.04M | |
$2,788,839 | 12 | 6.73% | $754.88M | |
$92,357,691 | 12 | 87.24% | $778.34M | |
Kura Oncology, Inc. (KURA) | $11,541,901 | 10 | 8.07% | $750.96M |
$140,543,039 | 10 | 0.77% | $651.98M | |
$38,624,786 | 9 | 1.26% | $738.45M | |
$94,000,000 | 7 | -20.84% | $799.66M | |
$51,588,185 | 5 | 19.18% | $718.13M | |
$7,234,370 | 3 | -3.34% | $677.47M | |
$3,850,000 | 1 | -51.32% | $698.09M | |
$13,900 | 1 | -39.25% | $780.84M |
| Increased Positions | 116 | +61.05% | 14M | +16.35% |
| Decreased Positions | 79 | -41.58% | 12M | -14.52% |
| New Positions | 40 | New | 3M | New |
| Sold Out Positions | 25 | Sold Out | 3M | Sold Out |
| Total Postitions | 227 | +19.47% | 84M | +1.83% |
| Blackrock, Inc. | $98,339.00 | 10.94% | 9.52M | +44,802 | +0.47% | 2025-09-30 |
| Bvf Inc/Il | $89,058.00 | 9.9% | 8.62M | +863,033 | +11.13% | 2025-09-30 |
| Suvretta Capital Management, Llc | $83,879.00 | 9.33% | 8.12M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $56,517.00 | 6.29% | 5.47M | +120,197 | +2.25% | 2025-09-30 |
| Armistice Capital, Llc | $48,285.00 | 5.37% | 4.67M | -2M | -24.64% | 2025-09-30 |
| State Street Corp | $34,551.00 | 3.84% | 3.34M | +306,273 | +10.09% | 2025-09-30 |
| Prosight Management, Lp | $28,509.00 | 3.17% | 2.76M | -422,668 | -13.29% | 2025-09-30 |
| Goldman Sachs Group Inc | $27,023.00 | 3.01% | 2.61M | +2M | +180.05% | 2025-09-30 |
| Aqr Capital Management Llc | $23,173.00 | 2.58% | 2.24M | +1M | +138.11% | 2025-09-30 |
| Jacobs Levy Equity Management, Inc | $22,991.00 | 2.56% | 2.22M | +1M | +101.62% | 2025-09-30 |